المؤلفون: Pollastro, Sabrina, Musters, Anne, Balzaretti, Giulia, Niewold, Ilse, van Schaik, Barbera, Hässler, Signe, Verhoef, Catharina M., Pallardy, Marc, van Kampen, Antoine, Mariette, Xavier, de Vries, Niek

المساهمون: Amsterdam UMC - Amsterdam University Medical Center, University of Amsterdam Amsterdam = Universiteit van Amsterdam (UvA), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Immunologie - Immunopathologie - Immunothérapie CHU Pitié Salpêtrière (I3), CHU Charles Foix AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre d'investigation clinique Biothérapie CHU Pitié-Salpêtrière (CIC-BTi), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Inflammation, microbiome, immunosurveillance (MI2), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre de recherche en Immunologie des Infections virales et des maladies auto-immunes, Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Saclay, Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Salima Hacein-Bey Abina, IMI-funded, ZonMw, ABIRISK Consortium: Natacha Szely, Aude Gleizes, Salima Hacein-Bey Abina, Christophe Richez, Martin Soubrier, Jérome Avouac, Olivier Brocq, Jérémie Sellam, Tom Huizinga, Elizabeth Jury, Jessica Manson, Claudia Mauri, Andrea Matucci

المصدر: ISSN: 1478-6354 ; Arthritis Research and Therapy ; https://hal.science/hal-04615209Test ; Arthritis Research and Therapy, 2024, 26 (1), pp.70. ⟨10.1186/s13075-024-03297-7⟩.

مصطلحات موضوعية: AIRR-seq, B cells, B-cell receptor repertoire, Rheumatoid arthritis, Rituximab, [SDV]Life Sciences [q-bio]

الوصف: International audience ; Background: Although B-cell depleting therapy in rheumatoid arthritis (RA) is clearly effective, response is variable and does not correlate with B cell depletion itself.Methods: The B-cell receptor (BCR) repertoire was prospectively analyzed in peripheral blood samples of twenty-eight RA patients undergoing rituximab therapy. Timepoints of achieved BCR-depletion and -repopulation were defined based on the percentage of unmutated BCRs in the repertoire. The predictive value of early BCR-depletion (within one-month post-treatment) and early BCR-repopulation (within 6 months post-treatment) on clinical response was assessed.Results: We observed changes in the peripheral blood BCR repertoire after rituximab treatment, i.e., increased clonal expansion, decreased clonal diversification and increased mutation load which persisted up to 12 months after treatment, but started to revert at month 6. Early BCR depletion was not associated with early clinical response but late depleters did show early response. Patients with early repopulation with unmutated BCRs showed a significant decrease in disease activity in the interval 6 to 12 months. Development of anti-drug antibodies non-significantly correlated with more BCR repopulation.Conclusion: Our findings indicate that rather than BCR-depletion it is repopulation with unmutated BCRs, possibly from naïve B cells, which induces remission. This suggests that (pre-existing) differences in B-cell turnover between patients explain the interindividual differences in early clinical effect.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/38493208; hal-04615209; https://hal.science/hal-04615209Test; https://hal.science/hal-04615209/documentTest; https://hal.science/hal-04615209/file/s13075-024-03297-7.pdfTest; PUBMED: 38493208; PUBMEDCENTRAL: PMC10943808

الإتاحة: https://doi.org/10.1186/s13075-024-03297-7Test
https://hal.science/hal-04615209Test
https://hal.science/hal-04615209/documentTest
https://hal.science/hal-04615209/file/s13075-024-03297-7.pdfTest

المؤلفون: Merino-Vico, Ana, van Hamburg, Jan Piet, Tuijnenburg, Paul, Frazzei, Giulia, Al-Soudi, Aram, Bonasia, Carlo G, Helder, Boy, Rutgers, Abraham, Abdulahad, Wayel H, Stegeman, Coen A, Sanders, Jan-Stephan, Bergamaschi, Laura, Lyons, Paul A, Bijma, Theo, van Keep, Laura, Wesenhagen, Kirsten, Jongejan, Aldo, Olsson, Henric, de Vries, Niek, Kuijpers, Taco W, Heeringa, Peter, Tas, Sander W

المصدر: Merino-Vico , A , van Hamburg , J P , Tuijnenburg , P , Frazzei , G , Al-Soudi , A , Bonasia , C G , Helder , B , Rutgers , A , Abdulahad , W H , Stegeman , C A , Sanders , J-S , Bergamaschi , L , Lyons , P A , Bijma , T , van Keep , L , Wesenhagen , K , Jongejan , A , Olsson , H , de Vries , N , Kuijpers , T W , Heeringa , P & Tas , S W 2024 , ....

الوصف: B lineage cells are critically involved in ANCA-associated vasculitis (AAV), evidenced by alterations in circulating B cell subsets and beneficial clinical effects of rituximab (anti-CD20) therapy. This treatment renders a long-term, peripheral B cell depletion, but allows for the survival of long-lived plasma cells. Therefore, there is an unmet need for more reversible and full B lineage cell targeting approaches. To find potential novel therapeutic targets, RNA sequencing of CD27 + memory B cells of patients with active AAV was performed, revealing an upregulated NF-κB-associated gene signature. NF-κB signaling pathways act downstream of various B cell surface receptors, including the BCR, CD40, BAFFR and TLRs, and are essential for B cell responses. Here we demonstrate that novel pharmacological inhibitors of NF-κB inducing kinase (NIK, non-canonical NF-κB signaling) and inhibitor-of-κB-kinase-β (IKKβ, canonical NF-κB signaling) can effectively inhibit NF-κB signaling in B cells, whereas T cell responses were largely unaffected. Moreover, both inhibitors significantly reduced B cell proliferation, differentiation and production of antibodies, including proteinase-3 (PR3) autoantibodies, in B lineage cells of AAV patients. These findings indicate that targeting NF-κB, particularly NIK, may be an effective, novel B lineage cell targeted therapy for AAV and other autoimmune diseases with prominent B cell involvement.

وصف الملف: application/pdf

العلاقة: https://research.rug.nl/en/publications/7f3e7eba-47fc-4afb-99b8-36f37a9374a6Test

الإتاحة: https://doi.org/10.1016/j.jaut.2023.103133Test
https://hdl.handle.net/11370/7f3e7eba-47fc-4afb-99b8-36f37a9374a6Test
https://research.rug.nl/en/publications/7f3e7eba-47fc-4afb-99b8-36f37a9374a6Test
https://pure.rug.nl/ws/files/829622856/71931511_5376182_jamadermatology_frie_2020_ld_190029.pdfTest

المؤلفون: Balashova, Daria, van Schaik, Barbera D. C., Stratigopoulou, Maria, Guikema, Jeroen E. J., Caniels, Tom G., Claireaux, Mathieu, van Gils, Marit J., Musters, Anne, Anang, Dornatien C., de Vries, Niek, Greiff, Victor, van Kampen, Antoine H. C.

المصدر: BMC Immunology ; volume 25, issue 1 ; ISSN 1471-2172

مصطلحات موضوعية: Immunology

الوصف: The reconstruction of clonal families (CFs) in B-cell receptor (BCR) repertoire analysis is a crucial step to understand the adaptive immune system and how it responds to antigens. The BCR repertoire of an individual is formed throughout life and is diverse due to several factors such as gene recombination and somatic hypermutation. The use of Adaptive Immune Receptor Repertoire sequencing (AIRR-seq) using next generation sequencing enabled the generation of full BCR repertoires that also include rare CFs. The reconstruction of CFs from AIRR-seq data is challenging and several approaches have been developed to solve this problem. Currently, most methods use the heavy chain (HC) only, as it is more variable than the light chain (LC). CF reconstruction options include the definition of appropriate sequence similarity measures, the use of shared mutations among sequences, and the possibility of reconstruction without preliminary clustering based on V- and J-gene annotation. In this study, we aimed to systematically evaluate different approaches for CF reconstruction and to determine their impact on various outcome measures such as the number of CFs derived, the size of the CFs, and the accuracy of the reconstruction. The methods were compared to each other and to a method that groups sequences based on identical junction sequences and another method that only determines subclones. We found that after accounting for data set variability, in particular sequencing depth and mutation load, the reconstruction approach has an impact on part of the outcome measures, including the number of CFs. Simulations indicate that unique junctions and subclones should not be used as substitutes for CF and that more complex methods do not outperform simpler methods. Also, we conclude that different approaches differ in their ability to correctly reconstruct CFs when not considering the LC and to identify shared CFs. The results showed the effect of different approaches on the reconstruction of CFs and highlighted the ...

الإتاحة: https://doi.org/10.1186/s12865-024-00600-8Test

المؤلفون: Anang, Dornatien C., Walter, Hannah A. W., Lim, Johan, Niewold, Ilse T. G., van der Weele, Linda, Aronica, Eleonora, Eftimov, Filip, Raaphorst, Joost, van Schaik, Barbera D. C., van Kampen, Antoine H. C., van der Kooi, Anneke J., de Vries, Niek

المصدر: Frontiers in Immunology ; volume 14 ; ISSN 1664-3224

مصطلحات موضوعية: Immunology, Immunology and Allergy

الوصف: Objectives To characterize the T cell receptor (TCRβ) repertoire in peripheral blood and muscle tissues of treatment naïve patients with newly diagnosed idiopathic inflammatory myopathies (IIMs). Methods High throughput RNA sequencing of the TCRβ chain was performed in peripheral blood and muscle tissue in twenty newly-diagnosed treatment-naïve IIM patients (9 DM, 5 NM/OM, 5 IMNM and 1 ASyS) and healthy controls. Results thereof were correlated with markers of disease activity. Results Muscle tissue of IIM patients shows more expansion of TCRβ clones and decreased diversity when compared to peripheral blood of IIM as well as healthy controls (both p=0.0001). Several expanded TCRβ clones in muscle are tissue restricted and cannot be retrieved in peripheral blood. These clones have significantly longer CDR3 regions when compared to clones (also) found in circulation (p=0.0002), while their CDR3 region is more hydrophobic (p<0.01). Network analysis shows that clonal TCRβ signatures are shared between patients. Increased clonal expansion in muscle tissue is significantly correlated with increased CK levels (p=0.03), while it tends to correlate with decreased muscle strength (p=0.08). Conclusion Network analysis of clones in muscle of IIM patients shows shared clusters of sequences across patients. Muscle-restricted CDR3 TCRβ clones show specific structural features in their T cell receptor. Our results indicate that clonal TCRβ expansion in muscle tissue might be associated with disease activity. Collectively, these findings support a role for specific clonal T cell responses in muscle tissue in the pathogenesis of the IIM subtypes studied.

الإتاحة: https://doi.org/10.3389/fimmu.2023.1279055Test

المؤلفون: Kuiper, Jonas Jw, Prinz, Jörg C, Stratikos, Efstratios, Kuśnierczyk, Piotr, Arakawa, Akiko, Springer, Sebastian, Mintoff, Dillon, Padjen, Ivan, Shumnalieva, Russka, Vural, Seçil, Kötter, Ina, van de Sande, Marleen G, Boyvat, Ayşe, de Boer, Joke H, Bertsias, George, de Vries, Niek, Krieckaert, Charlotte Lm, Leal, Inês, Vidovič Valentinčič, Nataša, Tugal-Tutkun, Ilknur, El Khaldi Ahanach, Hanane, Costantino, Félicie, Glatigny, Simon, Mrazovac Zimak, Danijela, Lötscher, Fabian, Kerstens, Floor G, Bakula, Marija, Viera Sousa, Elsa, Böhm, Peter, Bosman, Kees, Kenna, Tony J, Powis, Simon J, Breban, Maxime, Gul, Ahmet, Bowes, John, Lories, Rik Ju, Nowatzky, Johannes, Wolbink, Gerrit Jan, McGonagle, Dennis G, Turkstra, Franktien

المصدر: Kuiper , J J , Prinz , J C , Stratikos , E , Kuśnierczyk , P , Arakawa , A , Springer , S , Mintoff , D , Padjen , I , Shumnalieva , R , Vural , S , Kötter , I , van de Sande , M G , Boyvat , A , de Boer , J H , Bertsias , G , de Vries , N , Krieckaert , C L , Leal , I , Vidovič Valentinčič , N , Tugal-Tutkun , I , El Khaldi Ahanach , H , Costantino , F ....

الوصف: The 'MHC-I (major histocompatibility complex class I)-opathy' concept describes a family of inflammatory conditions with overlapping clinical manifestations and a strong genetic link to the MHC-I antigen presentation pathway. Classical MHC-I-opathies such as spondyloarthritis, Behçet's disease, psoriasis and birdshot uveitis are widely recognised for their strong association with certain MHC-I alleles and gene variants of the antigen processing aminopeptidases ERAP1 and ERAP2 that implicates altered MHC-I peptide presentation to CD8+T cells in the pathogenesis. Progress in understanding the cause and treatment of these disorders is hampered by patient phenotypic heterogeneity and lack of systematic investigation of the MHC-I pathway.Here, we discuss new insights into the biology of MHC-I-opathies that strongly advocate for disease-overarching and integrated molecular and clinical investigation to decipher underlying disease mechanisms. Because this requires transformative multidisciplinary collaboration, we introduce the EULAR study group on MHC-I-opathies to unite clinical expertise in rheumatology, dermatology and ophthalmology, with fundamental and translational researchers from multiple disciplines such as immunology, genomics and proteomics, alongside patient partners. We prioritise standardisation of disease phenotypes and scientific nomenclature and propose interdisciplinary genetic and translational studies to exploit emerging therapeutic strategies to understand MHC-I-mediated disease mechanisms. These collaborative efforts are required to address outstanding questions in the etiopathogenesis of MHC-I-opathies towards improving patient treatment and prognostication.

وصف الملف: application/pdf

العلاقة: https://research-portal.st-andrews.ac.uk/en/researchoutput/eular-study-group-on-mhciopathyTest(855b6975-14c8-479b-96a0-18e6dc2abbf8).html

الإتاحة: https://doi.org/10.1136/ard-2022-222852Test
https://research-portal.st-andrews.ac.uk/en/researchoutput/eular-study-group-on-mhciopathyTest(855b6975-14c8-479b-96a0-18e6dc2abbf8).html
https://research-repository.st-andrews.ac.uk/bitstream/10023/27375/1/Kuiper_2023_ARD_EULAR_study_group_CC.pdfTest

المؤلفون: Anang, Dornatien C., Walter, Hannah A. W., Lim, Johan, Niewold, Ilse T. G., van der Weele, Linda, Aronica, Eleonora, Eftimov, Filip, Raaphorst, Joost, van Schaik, Barbera D. C., van Kampen, Antoine H. C., van der Kooi, Anneke J., de Vries, Niek

المصدر: Anang , D C , Walter , H A W , Lim , J , Niewold , I T G , van der Weele , L , Aronica , E , Eftimov , F , Raaphorst , J , van Schaik , B D C , van Kampen , A H C , van der Kooi , A J & de Vries , N 2023 , ' TCRβ clones in muscle tissue share structural features in patients with idiopathic inflammatory myopathy and are associated with disease activity ' , Frontiers in Immunology , vol. 14 , 1279055 . https://doi.org/10.3389/fimmu.2023.1279055Test

الوصف: Objectives: To characterize the T cell receptor (TCRβ) repertoire in peripheral blood and muscle tissues of treatment naïve patients with newly diagnosed idiopathic inflammatory myopathies (IIMs). Methods: High throughput RNA sequencing of the TCRβ chain was performed in peripheral blood and muscle tissue in twenty newly-diagnosed treatment-naïve IIM patients (9 DM, 5 NM/OM, 5 IMNM and 1 ASyS) and healthy controls. Results thereof were correlated with markers of disease activity. Results: Muscle tissue of IIM patients shows more expansion of TCRβ clones and decreased diversity when compared to peripheral blood of IIM as well as healthy controls (both p=0.0001). Several expanded TCRβ clones in muscle are tissue restricted and cannot be retrieved in peripheral blood. These clones have significantly longer CDR3 regions when compared to clones (also) found in circulation (p=0.0002), while their CDR3 region is more hydrophobic (p<0.01). Network analysis shows that clonal TCRβ signatures are shared between patients. Increased clonal expansion in muscle tissue is significantly correlated with increased CK levels (p=0.03), while it tends to correlate with decreased muscle strength (p=0.08). Conclusion: Network analysis of clones in muscle of IIM patients shows shared clusters of sequences across patients. Muscle-restricted CDR3 TCRβ clones show specific structural features in their T cell receptor. Our results indicate that clonal TCRβ expansion in muscle tissue might be associated with disease activity. Collectively, these findings support a role for specific clonal T cell responses in muscle tissue in the pathogenesis of the IIM subtypes studied.

العلاقة: https://research.vumc.nl/en/publications/e3a24ea4-5f79-477d-9c89-7a15cfd63200Test

الإتاحة: https://doi.org/10.3389/fimmu.2023.1279055Test
https://research.vumc.nl/en/publications/e3a24ea4-5f79-477d-9c89-7a15cfd63200Test
https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85182821188&origin=inwardTest

المؤلفون: Frazzei, Giulia, Musters, Anne, de Vries, Niek, Tas, Sander W., van Vollenhoven, Ronald F.

المصدر: Frazzei , G , Musters , A , de Vries , N , Tas , S W & van Vollenhoven , R F 2023 , ' Prevention of rheumatoid arthritis : A systematic literature review of preventive strategies in at-risk individuals ' , Autoimmunity Reviews , vol. 22 , no. 1 , 103217 . https://doi.org/10.1016/j.autrev.2022.103217Test

الوصف: Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by symmetrical peripheral polyarthritis in the hands and/or feet, leading to long-term disability if not treated effectively. RA is preceded by a preclinical phase, in which genetically predisposed individuals accumulate environmental risk factors, and during which autoimmunity develops, followed by the emergence of non-specific signs and symptoms before arthritis becomes manifest. Early treatment in at-risk individuals – i.e. before the disease is fully established – has the theoretical potential to delay or prevent disease onset, with a positive impact on both patients' life and society. Objectives: We aimed to understand the feasibility of preventive treatment in at-risk individuals, taking into account recently performed studies and ongoing clinical trials, as well as patient perspectives. Methods: We performed a systematic literature review (SLR) on Medline and Embase, searching articles published between 2010 and 2021 with the following key-words: “Rheumatoid arthritis”, “arthralgia”, “pre-treatment” or “prevent”. Results: Our SLR identified a total of 1821 articles. Articles were independently screened by two researchers. A total of 14 articles were included after screening, and an additional 8 reports were manually included. We identified ten relevant clinical trials performed in at-risk individuals, or in individuals with undifferentiated inflammatory arthritis. Although no treatment was shown to prevent RA onset, early treatment with rituximab and abatacept delayed onset of full-blown RA, and both conventional and biological disease-modifying anti-rheumatic drugs (DMARDs) decreased disease-related physical limitations and increased DAS28-defined remission, at least temporarily. Conclusions: This SLR demonstrates that early treatment of at-risk individuals may be effective in delaying RA onset, thereby decreasing disease-related limitations in individuals in the pre-clinical phase of RA. Whether this may ultimately lead to ...

العلاقة: https://research.vumc.nl/en/publications/397fcab4-9005-47f3-9c5c-9f721255f331Test

الإتاحة: https://doi.org/10.1016/j.autrev.2022.103217Test
https://research.vumc.nl/en/publications/397fcab4-9005-47f3-9c5c-9f721255f331Test
http://www.scopus.com/inward/record.url?scp=85143485627&partnerID=8YFLogxKTest

المؤلفون: Anang, Dornatien C., Walter, Hannah A. W., Lim, Johan, Niewold, Ilse, van der Weele, Linda, Aronica, Eleonora, Eftimov, Filip, Raaphorst, Joost, van Schaik, Barbera D. C., van Kampen, Antoine H. C., van der Kooi, Anneke J., de Vries, Niek

المصدر: Anang , D C , Walter , H A W , Lim , J , Niewold , I , van der Weele , L , Aronica , E , Eftimov , F , Raaphorst , J , van Schaik , B D C , van Kampen , A H C , van der Kooi , A J & de Vries , N 2023 , ' B-cell receptor profiling before and after IVIG monotherapy in newly diagnosed idiopathic inflammatory myopathies ' , Rheumatology (United Kingdom) , vol. 62 , no. 7 , pp. 2585-2593 . https://doi.org/10.1093/rheumatology/keac602Test

الوصف: Objective: To unravel B-cell receptor (BcR) characteristics in muscle tissues and peripheral blood and gain more insight into BcR repertoire changes in peripheral blood in idiopathic inflammatory myopathies (IIMs), and study how this correlates to the clinical response to IVIG. Methods: Nineteen treatment-naive patients with newly diagnosed IIM were prospectively treated with IVIG monotherapy. RNA-based BcR repertoire sequencing was performed in muscle biopsies collected before, and in peripheral blood (PB) collected before and nine weeks after IVIG treatment. Results were correlated to patients' clinical improvement based on the total improvement score (TIS). Results: Prior to IVIG treatment, BcR clones found in muscle tissue could be retrieved in peripheral blood. Nine weeks after IVIG treatment, new patient-specific dominant BcR clones appeared in peripheral blood while pre-treatment dominant BcR clones disappeared. The cumulative frequency of all dominant BcR clones before treatment was significantly higher in individuals who responded to IVIG compared with those who did not respond to IVIG, and correlated with a higher CK. During follow-up, a decrease in the cumulative frequency of all dominant clones correlated with a higher TIS. Conclusion: In treatment-naive patients with newly diagnosed IIM, muscle tissue and peripheral blood share expanded BcR clones. In our study a higher cumulative frequency of dominant BcR clones in blood before treatment was associated with a higher CK and better treatment response, suggesting that response to IVIG may depend on the composition of the pre-treatment BcR repertoire.

العلاقة: https://research.vumc.nl/en/publications/dae894ed-4b78-40d8-9289-2bb2c0263770Test

الإتاحة: https://doi.org/10.1093/rheumatology/keac602Test
https://research.vumc.nl/en/publications/dae894ed-4b78-40d8-9289-2bb2c0263770Test
http://www.scopus.com/inward/record.url?scp=85164239296&partnerID=8YFLogxKTest

المؤلفون: Bitoun, Samuel, Hässler, Signe, Ternant, David, Szely, Natacha, Gleizes, Aude, Richez, Christophe, Soubrier, Martin J., Avouac, Jérôme, Brocq, Olivier, Sellam, Jérémie A.A., de Vries, Niek, Huizinga, Tom W.J., Jury, Elizabeth C., Manson, Jessica J., Mauri, Claudia, Matucci, Andrea, Hacein Bey Abina, Salima, Mulleman, Denis, Pallardy, Marc J., Broët, Philippe, Mariette, Xavier

المساهمون: Immunologie des Maladies Virales et Autoimmunes (IMVA - U1184), Université Paris-Sud - Paris 11 (UP11)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Bicêtre AP-HP, Le Kremlin-Bicêtre, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Immunologie - Immunopathologie - Immunothérapie CHU Pitié Salpêtrière (I3), CHU Charles Foix AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre d'investigation clinique Biothérapie CHU Pitié-Salpêtrière (CIC-BTi), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Nanomédicaments et Nanosondes (NMNS), Université de Tours (UT), Inflammation, microbiome, immunosurveillance (MI2), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, AP-HP. Université Paris Saclay, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS - UM 4 (UMR 8258 / U1267)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie - CNRS Chimie (INC-CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Pellegrin, CHU Bordeaux-Groupe hospitalier Pellegrin, CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand, Hôpital Cochin AP-HP, Université Paris Cité (UPCité), Centre Hospitalier Princesse Grace de Monaco (CHPG), Monaco, CHU Saint-Antoine AP-HP, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), University of Amsterdam Amsterdam = Universiteit van Amsterdam (UvA), Leiden University Medical Center (LUMC), Universiteit Leiden = Leiden University, University College of London London (UCL), University College London Hospitals (UCLH), Azienda Ospedaliero Universitaria Careggi Firenze = Careggi University Hospital Florence, Italy (AOUC)

المصدر: EISSN: 2574-3805 ; JAMA Network Open ; https://hal.science/hal-04191687Test ; JAMA Network Open, 2023, 6 (7), pp.e2323098. ⟨10.1001/jamanetworkopen.2023.23098⟩

مصطلحات موضوعية: [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie

الوصف: International audience ; Importance: There are conflicting data on the association of antidrug antibodies with response to biologic disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA).Objective: To analyze the association of antidrug antibodies with response to treatment for RA.Design, Setting, and Participants: This cohort study analyzed data from the ABI-RA (Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients) multicentric, open, prospective study of patients with RA from 27 recruiting centers in 4 European countries (France, Italy, the Netherlands, and the UK). Eligible patients were 18 years or older, had RA diagnosis, and were initiating a new bDMARD. Recruitment spanned from March 3, 2014, to June 21, 2016. The study was completed in June 2018, and data were analyzed in June 2022.Exposures: Patients were treated with a new bDMARD: adalimumab, infliximab (grouped as anti-tumor necrosis factor [TNF] monoclonal antibodies [mAbs]), etanercept, tocilizumab, and rituximab according to the choice of the treating physician.Main Outcomes and Measures: The primary outcome was the association of antidrug antibody positivity with EULAR (European Alliance of Associations for Rheumatology; formerly, European League Against Rheumatism) response to treatment at month 12 assessed through univariate logistic regression. The secondary end points were the EULAR response at month 6 and at visits from month 6 to months 15 to 18 using generalized estimating equation models. Detection of antidrug antibody serum levels was performed at months 1, 3, 6, 12, and 15 to 18 using electrochemiluminescence (Meso Scale Discovery) and drug concentration for anti-TNF mAbs, and etanercept in the serum was measured using enzyme-linked immunosorbent assay.Results: Of the 254 patients recruited, 230 (mean [SD] age, 54.3 [13.7] years; 177 females [77.0%]) were analyzed. At month 12, antidrug antibody positivity was 38.2% ...

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37436748; hal-04191687; https://hal.science/hal-04191687Test; https://hal.science/hal-04191687/documentTest; https://hal.science/hal-04191687/file/bitoun_2023_oi_230683_1688565285.41453.pdfTest; PUBMED: 37436748; PUBMEDCENTRAL: PMC10339150

الإتاحة: https://doi.org/10.1001/jamanetworkopen.2023.23098Test
https://hal.science/hal-04191687Test
https://hal.science/hal-04191687/documentTest
https://hal.science/hal-04191687/file/bitoun_2023_oi_230683_1688565285.41453.pdfTest

المؤلفون: Kuiper, Jonas Jw, Prinz, Jörg C, Stratikos, Efstratios, Kuśnierczyk, Piotr, Arakawa, Akiko, Springer, Sebastian, Mintoff, Dillon, Padjen, Ivan, Shumnalieva, Russka, Vural, Seçil, Kötter, Ina, van de Sande, Marleen G, Boyvat, Ayşe, de Boer, Joke H, Bertsias, George, de Vries, Niek, Krieckaert, Charlotte Lm, Leal, Inês, Vidovič Valentinčič, Nataša, Tugal-Tutkun, Ilknur, El Khaldi Ahanach, Hanane, Costantino, Félicie, Glatigny, Simon, Mrazovac Zimak, Danijela, Lötscher, Fabian, Kerstens, Floor G, Bakula, Marija, Viera Sousa, Elsa, Böhm, Peter, Bosman, Kees, Kenna, Tony J, Powis, Simon J, Breban, Maxime, Gul, Ahmet, Bowes, John, Lories, Rik Ju, Nowatzky, Johannes, Wolbink, Gerrit Jan, McGonagle, Dennis G, Turkstra, Franktien

المصدر: Kuiper, Jonas Jw; Prinz, Jörg C; Stratikos, Efstratios; Kuśnierczyk, Piotr; Arakawa, Akiko; Springer, Sebastian; Mintoff, Dillon; Padjen, Ivan; Shumnalieva, Russka; Vural, Seçil; Kötter, Ina; van de Sande, Marleen G; Boyvat, Ayşe; de Boer, Joke H; Bertsias, George; de Vries, Niek; Krieckaert, Charlotte Lm; Leal, Inês; Vidovič Valentinčič, Nataša; Tugal-Tutkun, Ilknur; . (2023). EULAR study group on 'MHC-I-opathy': identifying disease-overarching mechanisms across disciplines and borders. Annals of the rheumatic diseases, 82(7), pp. 887-896. BMJ Publishing Group 10.1136/ard-2022-222852

مصطلحات موضوعية: 610 Medicine & health

الوصف: The 'MHC-I (major histocompatibility complex class I)-opathy' concept describes a family of inflammatory conditions with overlapping clinical manifestations and a strong genetic link to the MHC-I antigen presentation pathway. Classical MHC-I-opathies such as spondyloarthritis, Behçet's disease, psoriasis and birdshot uveitis are widely recognised for their strong association with certain MHC-I alleles and gene variants of the antigen processing aminopeptidases ERAP1 and ERAP2 that implicates altered MHC-I peptide presentation to CD8+T cells in the pathogenesis. Progress in understanding the cause and treatment of these disorders is hampered by patient phenotypic heterogeneity and lack of systematic investigation of the MHC-I pathway.Here, we discuss new insights into the biology of MHC-I-opathies that strongly advocate for disease-overarching and integrated molecular and clinical investigation to decipher underlying disease mechanisms. Because this requires transformative multidisciplinary collaboration, we introduce the EULAR study group on MHC-I-opathies to unite clinical expertise in rheumatology, dermatology and ophthalmology, with fundamental and translational researchers from multiple disciplines such as immunology, genomics and proteomics, alongside patient partners. We prioritise standardisation of disease phenotypes and scientific nomenclature and propose interdisciplinary genetic and translational studies to exploit emerging therapeutic strategies to understand MHC-I-mediated disease mechanisms. These collaborative efforts are required to address outstanding questions in the etiopathogenesis of MHC-I-opathies towards improving patient treatment and prognostication.

وصف الملف: application/pdf

العلاقة: https://boris.unibe.ch/181065Test/

الإتاحة: https://doi.org/10.1136/ard-2022-222852Test
https://boris.unibe.ch/181065/1/ard-2022-222852.full.pdfTest
https://boris.unibe.ch/181065Test/